Geron (STU:GON) ROE % Adjusted to Book Value : -13.29% (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Geron ROE % Adjusted to Book Value?

Geron's ROE % for the quarter that ended in Mar. 2024 was -74.85%. Geron's PB Ratio for the quarter that ended in Mar. 2024 was 5.63. Geron's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -13.29%.

Geron ROE % Adjusted to Book Value Historical Data

The historical data trend for Geron's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geron ROE % Adjusted to Book Value Chart

Geron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-21.14

-18.89

-22.87

-14.25

-24.08

Geron Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-22.78	-11.56	-15.60	-16.48	-13.29

Competitive Comparison of Geron's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Geron's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Geron's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geron's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Geron's ROE % Adjusted to Book Value falls into.

Geron ROE % Adjusted to Book Value Calculation

Geron's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-111.49%	/	4.63
	=	-24.08%

Geron's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-74.85%	/	5.63
	=	-13.29%

Geron ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Geron's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Geron (STU:GON) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (STU:GON) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

GERN:USA

Address

919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404

Website

https://www.geron.com

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.

Geron (STU:GON) Headlines

No Headlines